Results 61 to 70 of about 451,756 (297)

Transparency and Innuendo: An Alternative to Reactive Over-Disclosure [PDF]

, 2006
Lassman examines the tension between transparency and other public health interests in the context of the FDA\u27s proposed Drug Watch web site. He argues that although the FDA proposal seeks to achieve a laudable goal--the prompt communication of ...
Lassman, Scott M.
core   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Uso de medicamentos off-label e não licenciados em unidade de tratamento intensivo neonatal e sua associação com escores de gravidade Use of off-label and unlicensed drugs in the neonatal intensive care unit and its association with severity scores

Jornal de Pediatria, 2012
OBJETIVO: Avaliar a frequência da prescrição de medicamentos de uso não licenciado (UL) e off-label (OL) em recém-nascidos internados em unidade de tratamento intensivo neonatal de hospital de nível terciário e verificar a associação do seu uso com a ...
Clarissa G. Carvalho, Mariana R. Ribeiro, Mariana M. Bonilha, Mauro Fernandes Jr, Renato S. Procianoy, Rita C. Silveira   +5 more
doaj  

Assessment of primary labeling of medicines manufactured by Nepalese pharmaceutical industries

Journal of Pharmaceutical Policy and Practice, 2018
Background Appropriate labeling of marketed medicines is necessary to fulfill the regulatory provisions and ensure patient medication safety.
Ramesh Sharma Poudel, Shakti Shrestha, Santosh Thapa, Bhupendra Kumar Poudel, Muniraj Chhetri   +4 more
doaj   +1 more source

Analysis of the Costs Associated With the Elective Evaluation of Patients Labelled as Allergic to Beta-Lactams or Nonsteroidal Antiinflamatory Agents

Frontiers in Pharmacology, 2020
Introduction: Being labelled as allergic to different drugs results in patients receiving other treatments, which are more toxic, less effective and more expensive.
Miriam Sobrino-García, Esther M. Moreno, Esther M. Moreno, Esther M. Moreno, Esther M. Moreno, Francisco J. Muñoz-Bellido, Francisco J. Muñoz-Bellido, Francisco J. Muñoz-Bellido, Maria T. Gracia-Bara, Maria T. Gracia-Bara, Elena Laffond, Elena Laffond, Elena Laffond, Inmaculada Doña, Inmaculada Doña, Inmaculada Doña, Cristina Martín, Cristina Martín, Eva M. Macías, Eva M. Macías, Eva M. Macías, Sonia de Arriba, Sonia de Arriba, Sonia de Arriba, Valle Campanón, Alicia Gallardo, Ignacio Dávila, Ignacio Dávila, Ignacio Dávila, Ignacio Dávila   +29 more
doaj   +1 more source

Balancing Consumer Protection and Scientific Integrity in the Face of Uncertainty: The Example of Gluten-Free Foods [PDF]

, 2010
In 2009, gluten-free foods were not only hot in the marketplace, several countries, including the United States, continued efforts to define gluten-free and appropriate labeling parameters.
McCabe, Margaret Sova
core   +1 more source

Effective Feature Representation for Clinical Text Concept Extraction

, 2019
Crucial information about the practice of healthcare is recorded only in free-form text, which creates an enormous opportunity for high-impact NLP. However, annotated healthcare datasets tend to be small and expensive to obtain, which raises the question
Genthial, Guillaume, Godefroy, Bruno, Potts, Christopher, Tao, Yifeng   +3 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

First Amendment Scrutiny of FDA'S Fight Against Misbranding: Placing Labeling on the Spectrum of Speech [PDF]

, 2012
In order to further the Food and Drug Administration's (FDA) mission of "assur[ing] that the products it regulates are safe and truthfully labeled," the Federal Food, Drug, and Cosmetic Act (FD&C Act) gives FDA the power to enforce prohibitions on ...
Weissman, Kenneth I.
core  

The PI3Kδ inhibitor roginolisib (IOA‐244) preserves T‐cell function and activity

Molecular Oncology, EarlyView.
Identification of novel PI3K inhibitors with limited immune‐related adverse effects is highly sought after. We found that roginolisib and idelalisib inhibit chronic lymphocytic leukemia (CLL) cells and Treg suppressive functions to similar extents, but roginolisib affects cytotoxic T‐cell function and promotion of pro‐inflammatory T helper subsets to a
Elise Solli, Alessio Bevilacqua, Mathias Wenes, Denis Migliorini, Lars van der Veen, Sigrid S Skånland, Giusy Di Conza, Kjetil Taskén   +7 more
wiley   +1 more source